17

2020-09

Acne Drug KX-826 Gel Approved for Clinical Trials in China

On 17 September 2020, 真人直营投注网站 is pleased to announce that it has received clinical trial approval from the National Medical Products Administration for the gel dosage form of KX-826 for the treatment of acne and androgenetic alopecia.

14

2020-09

Kintor Pharma to Apply to Launch its Prostate Cancer Drug Next Season

In an interview with the Hong Kong Economic Journal, Kintor Pharmaceutical's (09939) Chief Financial Officer Lu Yan noted that the company will submit its new drug application (NDA) for its core product GT0918 for the treatment of prostate cancer next season.

11

2020-09

Kintor Pharma Makes Double Lists of “Comprehensive Pharmaceutical R&D Strength Rankings in China for 2020” and TOP100 Chemical Drug Research and Development Strength Rankings in China for 2020

Among them, 真人直营投注网站 was listed on the TOP100 Chemical Drug Research and Development Strength Rankings in China for 2020, and was also selected to enter the most important sub-list "TOP100 Chemical Pharmaceutical Research and Development Strength Rankings in China for 2020".

02

2020-09

China’s New Drugs on Way to Treating Male Baldness

According to the Insight database, KX-826, a drug of Chinese drugmaker Kintor Pharmaceutical currently in phase II clinical phase, has also been developed for the treatment of AGA.

01

2020-09

Kintor Pharmaceutical Enters Loncar China BioPharma Index after 100 Days of Listing in HK

In August 2020, the Loncar China BioPharma Index underwent its six-monthly adjustments and restructuring, adding 14 biopharmaceutical companies, including 真人直营投注网站 (stock code: 9939.HK).

01

2020-09

Three Parties Jointly Build A Precise Cancer Treatment Platform

(September 1, 2020, Hong Kong) 真人直营投注网站 (stock code: 9939, hereinafter referred to as “Kintor Pharmaceutical” or the “Company”) signed a strategic cooperation framework agreement with Suzhou GloriousMed Biomedical Group Co., Ltd. (hereinafter referred to as “GloriousMed”) and HM Shuke (Beijing) Medical Technology Co., Ltd. (hereinafter referred to as “HM Healthcare”), under which the three parties will create a patient-centered, integrated precise cancer treatment platform.

< 1...171819...24 > proceed page

Kintor